Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C

Digestive and Liver Disease

Volumn 41, Issue 7, 2009, Pages e4-

  Balderramo, D C ^a   Garcia O ^a   Colmenero, J ^a   Espinosa, G ^a   Forns, X ^a   Gines P ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiphospholipid syndrome; Hepatitis C virus; Pegylated interferon alpha

Indexed keywords

CEFIXIME; CEFTRIAXONE; ENOXAPARIN; HEPARIN; HYDROCORTISONE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; HEMATOMA; HEPATITIS C; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; PYELONEPHRITIS; SUBCLAVIAN VEIN; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 67349138574     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.11.029     Document Type: Article

References (14)

1. Hoofnagle J.H., and Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355 (2006) 2444-2451
2. Leroy V., Arvieux J., Jacob M.C., Maynard-Muet M., Baud M., and Zarski J.P. Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C. Br J Haematol 101 (1998) 468-474
3. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
4. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027
5. Espinosa G., Santos E., Cervera R., Piette J.C., de la Red G., Gil V., et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 82 (2003) 106-118
6. Ramos-Casals M., and Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 17 (2005) 447-455
7. Munoz-Rodriguez F.J., Tassies D., Font J., Reverter J.C., Cervera R., Sanchez-Tapias J.M., et al. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol 30 (1999) 770-773
8. Prieto J., Yuste J.R., Beloqui O., Civeira M.P., Riezu J.I., Aguirre B., et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 23 (1996) 199-204
9. Harada M., Fujisawa Y., Sakisaka S., Kawaguchi T., Taniguchi E., Sakamoto M., et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol 35 (2000) 272-277
10. Ordi-Ros J., Villarreal J., Monegal F., Sauleda S., Esteban I., and Vilardell M. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol 7 (2000) 241-244
11. Matsuda J., Saitoh N., Gotoh M., Gohchi K., Tsukamoto M., Syoji S., et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 90 (1995) 1138-1141
12. Carmona-Soria I., Jimenez-Saenz M., Gonzalez-Vilches J., and Herrerias-Gutierrez J.M. Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C. J Hepatol 34 (2001) 965-967
13. Becker J.C., Winkler B., Klingert S., and Bröcker E.B. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73 (1994) 1621-1624
14. Wilson L.E., Widman D., Dikman S.H., and Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32 (2002) 163-173